Scott David Solomon

Brigham and Women's Hospital (US)

Research Areas

Discover Papers by Scott David Solomon

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

192

Publications

2202

Citations

188896

i10-index

1145

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Recommendations for Chamber Quantification: A Repo...	2005	11351
Dapagliflozin in Patients with Heart Failure and R...	2019	7100
Guidelines for the Echocardiographic Assessment of...	2010	7060
Angiotensin–Neprilysin Inhibition versus Enalapril...	2014	6947
Cardiac-Resynchronization Therapy for the Preventi...	2009	3160
Patisiran, an RNAi Therapeutic, for Hereditary Tra...	2018	3031
Dapagliflozin in Heart Failure with Mildly Reduced...	2022	2849
Spironolactone for Heart Failure with Preserved Ej...	2014	2803
Valsartan, Captopril, or Both in Myocardial Infarc...	2003	2488
Angiotensin–Neprilysin Inhibition in Heart Failure...	2019	2423

Publications

1.
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
Year: 2005Citations: 11351DOI: 10.1016/j.echo.2005.10.005
2.
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Year: 2019Citations: 7100DOI: 10.1056/nejmoa1911303
3.
Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography
Year: 2010Citations: 7060DOI: 10.1016/j.echo.2010.05.010
4.
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
Year: 2014Citations: 6947DOI: 10.1056/nejmoa1409077
5.
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
Year: 2009Citations: 3160DOI: 10.1056/nejmoa0906431
6.
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Year: 2018Citations: 3031DOI: 10.1056/nejmoa1716153
7.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Year: 2022Citations: 2849DOI: 10.1056/nejmoa2206286
8.
Spironolactone for Heart Failure with Preserved Ejection Fraction
Year: 2014Citations: 2803DOI: 10.1056/nejmoa1313731
9.
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Year: 2003Citations: 2488DOI: 10.1056/nejmoa032292
10.
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Year: 2019Citations: 2423DOI: 10.1056/nejmoa1908655

About Scott David Solomon

Scott David Solomon is a researcher with 2202 publications and 188896 citations. They are affiliated with Brigham and Women's Hospital. Their research focuses on . With an h-index of 192, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Scott David Solomon and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year